Bath Savings Trust Co Has $1.48 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Bath Savings Trust Co cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 62.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,977 shares of the medical research company’s stock after selling 32,577 shares during the period. Bath Savings Trust Co’s holdings in Edwards Lifesciences were worth $1,479,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Nordea Investment Management AB grew its holdings in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares during the period. AIA Group Ltd grew its stake in Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after acquiring an additional 358,556 shares during the period. RiverPark Advisors LLC raised its holdings in Edwards Lifesciences by 58.1% during the third quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after buying an additional 7,583 shares during the last quarter. Finally, Banque Cantonale Vaudoise lifted its position in Edwards Lifesciences by 46.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock valued at $5,353,000 after acquiring an additional 25,886 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.60 during trading on Tuesday, hitting $74.14. 1,130,095 shares of the company’s stock were exchanged, compared to its average volume of 3,683,541. The stock has a market capitalization of $43.73 billion, a price-to-earnings ratio of 10.70, a PEG ratio of 3.63 and a beta of 1.11. The business has a 50-day simple moving average of $71.18 and a 200-day simple moving average of $72.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,500 shares of company stock worth $2,508,350. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Barclays boosted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Finally, Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.